Background: Ro autoantigens are of clinical significance because antibodies directed against them are found in most patients with primary Sjogren syndrome, subacute cutaneous lupus erythematosus (SLE), neonatal lupus erythematosus, ANA-negative lupus erythematosus, and systemic lupus erythematosus-like disease secondary to homozygous C2 or C4 complement deficiency. Ro/SSA is a ribonucleoprotein that binds to autoantibodies in 35 to 50% of patients with SLE and in up to 97% of patients with Sjogren syndrome. The Ro/SSA particle consists of a single immunoreactive protein noncovalently bound with one of four small RNA molecules. Most anti-Ro/SSA-positive sera antibodies detect not only the main protein, but also a smaller Ro/SSA protein. The genes which encode the smaller and larger proteins map to human chromosomes 11p15.5 and 1q31, respectively. La/SSB is an autoimmune RNA-binding protein that plays a role in the transcription of RNA polymerase III was originally defined by its reactivity with autoantibodies from patients with Sjogren syndrome and SLE.
Description: Rabbit polyclonal to SSA2
Immunogen: KLH conjugated synthetic peptide derived from SSA2
Specificity: ·Reacts with Human, Mouse and Rat.
·Isotype: IgG
Application: ·Western blotting: 1/100-500. Predicted Mol wt: 61 kDa;
·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;
·Immunocytochemistry: 1/100;
·Immunofluorescence: 1/50-200;
·ELISA: 1/500;
·Optimal working dilutions must be determined by the end user.
